Reduction in itch in 3 pivotal trials
≥4-point reduction in
weekly average of
Worst Scratch/Itch NRS
at Week 16
(secondary endpoint)1,2,a,b
≥4-point reduction in
Peak Pruritus NRS at Week 16
(secondary endpoint)1,3,4,a,b
≥4-point reduction in
Peak Pruritus NRS at Week 16
(secondary endpoint)1,3,4,a,b
The results present are not intended to be comparative across clinical trials.
aFull analysis set includes all subjects randomized.1
bIn the primary analyses of the efficacy endpoints, subjects who received rescue treatment or with missing data were considered nonresponders.1
In DUPIXENT pivotal clinical trials in AD, itch was measured using a 0- to 10-point numerical rating scale (NRS) assessing a patient’s worst itch over the previous 24 hours.
To calculate5:
- Peak Pruritus NRS asks patients who can self-report (6+ years of age): "On a scale of 0 to 10, how would you rate your itch overall (on average) during the previous 24 hours?"
- Worst Scratch/Itch NRS asks caregivers of children aged 6 months to 5 years: "On a scale of 0 to 10, how would you rate the scratching/itching of the child you are a caregiver for at its worst during the previous 24 hours?"
A reduction of ≥4 points from baseline is a clinically meaningful change.1
See itch relief data in other AD populations
Watch healthcare providers discuss itch relief with DUPIXENT
AD, atopic dermatitis; NRS, numerical rating scale; Q2W, every 2 weeks; Q4W, every 4 weeks; TCS, topical corticosteroids.